logo

PAHC

Phibro Animal Health·NASDAQ
--
--(--)
--
--(--)
8.21 / 10
Outperform

PAHC exhibits superior fundamental metrics, scoring 8.2/10. Key strengths include high Asset-MV, Net income-Revenue, and Cash-MV factors, with strong year-over-year growth in earnings per share and net profit. However, caution is advised for Net cash flow from operating activities due to negative YoY growth. The fundamental structure is robust, supporting an Outperform rating, but the negative Revenue-MV factor indicates potential valuation concerns. Overall, the fundamentals provide a solid foundation, yet some areas warrant monitoring for any deterioration.

Fundamental(8.21)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value1.23
Score0/3
Weight-6.79%
1M Return-2.93%
Net cash flow from operating activities per share (YoY growth rate %)
Value-8.60
Score2/3
Weight3.85%
1M Return1.41%
Net income-Revenue
Value-1.09
Score2/3
Weight7.29%
1M Return2.86%
Basic earnings per share (YoY growth rate %)
Value1883.33
Score3/3
Weight13.88%
1M Return4.75%
Total profit (YoY growth rate %)
Value522.87
Score3/3
Weight18.06%
1M Return6.14%
Net cash flow from operating activities (YoY growth rate %)
Value-8.53
Score1/3
Weight1.57%
1M Return0.62%
Diluted earnings per share (YoY growth rate %)
Value1883.33
Score3/3
Weight15.01%
1M Return5.10%
Asset-MV
Value-0.50
Score3/3
Weight12.51%
1M Return4.29%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value1897.68
Score3/3
Weight11.91%
1M Return4.09%
Cash-MV
Value-0.19
Score3/3
Weight22.70%
1M Return7.22%
Is PAHC undervalued or overvalued?
  • PAHC scores 8.21/10 on fundamentals and holds a Discounted valuation at present. Backed by its 17.47% ROE, 6.29% net margin, 23.36 P/E ratio, 6.47 P/B ratio, and 372.92% earnings growth, these metrics solidify its Outperform investment rating.